Table II.
Association between miR-671-3p expression and clinicopathological parameters of patients (n=38).
| Characteristic | Group | Count | miR-671-3p expression
|
P-value | |
|---|---|---|---|---|---|
| Low (%) | High (%) | ||||
| Age (years) | ≤50 | 18 | 11 (61.1) | 7 (38.9) | 0.532 |
| >50 | 20 | 10 (50) | 10 (50) | ||
| Tumor size | ≤2.5 cm | 11 | 7 (63.6) | 4 (36.4) | 0.721 |
| >2.5 cm | 27 | 14 (51.9) | 13 (48.1) | ||
| Pathological grade | IDC I | 5 | 3 (60) | 2 (40) | 0.396 |
| IDC II | 24 | 15 (62.5) | 9 (37.5) | ||
| IDC III | 9 | 3 (33.3) | 6 (66.7) | ||
| T stage | T1-T2 | 30 | 17 (56.7) | 13 (43.3) | 1 |
| T3-T4 | 8 | 4 (50) | 4 (50) | ||
| N stage | N0 | 18 | 10 (55.6) | 8 (44.4) | 1 |
| N1-N3 | 20 | 11 (55) | 9 (45) | ||
| M stage | M0 | 38 | 21 (55.3) | 17 (44.7) | – |
| M1 | 0 | – | – | ||
| TNM stage | I | 6 | 4 (66.7) | 2 (33.3) | 0.91 |
| II | 19 | 10 (52.6) | 9 (47.4) | ||
| III | 13 | 7 (46.2) | 6 (53.8) | ||
| Molecular subtype | Luminal | 10 | 6 (60) | 4 (40) | 0.315 |
| Her2-positive | 18 | 7 (38.9) | 11 (61.1) | ||
| Triple negative | 10 | 7 (70) | 3 (30) | ||
| ER/PR | Negative | 28 | 15 (53.6) | 13 (46.4) | 1 |
| Positive | 10 | 6 (60) | 4 (40) | ||
| Her2 | Negative | 20 | 14 (70) | 6 (30) | 0.101 |
| Positive | 18 | 7 (38.9) | 11 (61.1) | ||
miR, microRNA; IDC, invasive ductal carcinoma; ER/PR, estrogen receptors/progesterone receptors; Her2, human epidermal growth factor receptor 2.